Allison Whitten, PhD
Allison Whitten earned her PhD from Vanderbilt University in 2018 and continued her scientific training at Vanderbilt as a National Institute of Biomedical Imaging and Bioengineering (NIBIB) Postdoctoral Fellow. Her PhD and postdoctoral studies investigated the neurobiological causes of language impairments in neurological disorders. In 2020, she was awarded an AAAS Mass Media Fellowship to write for Discover Magazine. Her work has also appeared in WIRED, Quanta Magazine, Ars Technica, and more.
Articles by Allison Whitten, PhD
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline.
| 7 min read
They’re approved by the FDA and Medicare and inching closer to widespread adoption nationally. But how good are they at detecting colorectal cancer?
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
| 7 min read
While amyloid plaques form first, new work suggests targeting tau tangles that spread through the brain could also help the fight against this devastating disease.
| 3 min read
Scientists created a novel platform that uses the advantages of both bacteria and viruses to attack tumors.
| 4 min read
New vaccines and antiviral injections that could offer significantly better and broader protection against the flu are now in clinical trials.
| 4 min read
For the first time, researchers observed new conformational states between opioid drugs binding to mu opioid receptors — findings that drug developers can use to design safer opioid drugs.
| 2 min read
With so many cancer patients not responding to these immunotherapies, researchers are looking for new ways to boost their efficacy.
| 3 min read
The sensor could be used to enhance personalized medicine approaches for a variety of conditions.
| 5 min read
Pulmonary fibrosis patients have long suffered through side effects from their drugs. That could change with the potential for new inhaled versions in clinical trials.
| 3 min read
A new study showed that adding a drug to inhibit the OPA1 protein could reverse resistance to a frontline treatment in patients with AML.
| 3 min read
People with erythropoietic protoporphyria (EPP) must go to great lengths to avoid sun exposure. There have been no approved treatments that address the disease mechanism, but a new drug could change that.
